0000000000671801

AUTHOR

J. Bailey

showing 6 related works from this author

SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study

2021

Abstract Background Preoperative SARS-CoV-2 vaccination could support safer elective surgery. Vaccine numbers are limited so this study aimed to inform their prioritization by modelling. Methods The primary outcome was the number needed to vaccinate (NNV) to prevent one COVID-19-related death in 1 year. NNVs were based on postoperative SARS-CoV-2 rates and mortality in an international cohort study (surgical patients), and community SARS-CoV-2 incidence and case fatality data (general population). NNV estimates were stratified by age (18–49, 50–69, 70 or more years) and type of surgery. Best- and worst-case scenarios were used to describe uncertainty. Results NNVs were more favourable in su…

MaleCOVID-19 Vaccinesafe surgery; vaccination modelling; COVID-19Vascular damage Radboud Institute for Health Sciences [Radboudumc 16]MULTICENTERComorbidity030230 surgery0302 clinical medicinephase 3 clinical trial (topic)Case fatality rateProspective StudiesSARS-CoV-2 Vaccination Safe surgeryCOVID-19/epidemiologySARS-CoV-2 ; vaccination ; safe surgeryeducation.field_of_studycase fatality rateVaccinationVaccinationAdolescent; Adult; Aged; COVID-19; COVID-19 Vaccines; Comorbidity; Elective Surgical Procedures; Female; Humans; Male; Middle Aged; Postoperative Complications; Preoperative Period; Prospective Studies; SARS-CoV-2; Vaccination; Young Adulthealth care policyElective Surgical Procedures030220 oncology & carcinogenesisvaccination modellingPreoperative PeriodCOVID-19; SARS-CoV-2; cancer; vaccination; outcome; mortality; infection; modellingCohort studyprospective studyHumanmedicine.medical_specialtyArticle03 medical and health sciencesSARS-CoV-2 vaccinationSDG 3 - Good Health and Well-beingCOVID-19 Vaccines/pharmacologyHumansVaccination/methodsElective surgeryeducationAgedScience & TechnologyElective Surgical Procedureadult; aged; Article; cancer grading; cancer surgery; case fatality rate; computer assisted tomography; elective surgery; female; follow up; health care policy; human; incidence; infection rate; infection risk; major clinical study; male; middle aged; mortality; outcome assessment; phase 3 clinical trial (topic); preoperative care; prospective study; sensitivity analysis; seroprevalence; Severe acute respiratory syndrome coronavirus 2; vaccination; young adult; COVID-19; COVID-19 Vaccines; Comorbidity; Elective Surgical Procedures; Postoperative Complications; Preoperative Period; SARS-CoV-2; Vaccination; surgery.Cura preoperatòriamajor clinical studymortalityinfectionProspective StudieincidenceSurgeryHuman medicinePostoperative Complication610 Medizin und GesundheitAcademicSubjects/MED00910Settore MED/18 - CHIRURGIA GENERALESettore MED/29 - CHIRURGIA MAXILLOFACCIALEcomputer assisted tomographyESTUDOS PROSPECTIVOSsurgerysafe surgeryPostoperative Complicationssensitivity analysisSevere acute respiratory syndrome coronavirus 2preoperative careVacunacióProspective cohort studyseroprevalenceIncidence (epidemiology)covidElective Surgical Procedures/methodsMiddle Agedcancer gradingCOVID vaccinationoutcome/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingSARS-CoV-2; vaccination; surgeryOriginal ArticleFemalecancer surgeryAcademicSubjects/MED00010Life Sciences & BiomedicineAdultCOVID-19 VaccinesAdolescentinternational prospective cohort studyPostoperative Complications/prevention & controlPopulationinfection rateSARS-CoV-2/immunologyNOmodellingYoung Adultmedicinefollow upcancerddc:610infection riskoutcome assessmentLS7_4business.industrySARS-CoV-2Number needed to vaccinatePreoperative careCOVID-193126 Surgery anesthesiology intensive care radiologySettore MED/18Reconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10]elective surgeryEmergency medicinebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe British Journal of Surgery
researchProduct

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabin…

2019

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic failure [VF] allowed) were randomized (2:1) to D/C/F/TAF or boosted protease inhibitor (PI) plus emtricitabine/tenofovir-disoproxil-fumarate (F/TDF) over 48 weeks. At week 52 participants in the boosted PI arm were offered switch to D/C/F/TAF (late-switch, 44 weeks D/C/F/TAF exposure). All participants were followed on D/C/F/TAF until week 96. Efficacy endpoints were percentage cumulative protocol-defined virologic rebound (PDVR; confirmed vira…

MaleDOLUTEGRAVIRSustained Virologic ResponseHIV InfectionsGastroenterologychemistry.chemical_compound0302 clinical medicineMedicine and Health SciencesEmtricitabine030212 general & internal medicinePharmacology & PharmacyDarunavir0303 health sciencesAlanineDrug SubstitutionCobicistatEmtricitabine Tenofovir Disoproxil Fumarate Drug CombinationLamivudineAntiretroviralsMiddle AgedViral LoadOPEN-LABEL3. Good healthWEIGHT-GAINDrug CombinationsTreatment OutcomeDolutegravirNON-INFERIORITYFemaleSafetyViral loadLife Sciences & Biomedicinemedicine.drugTabletsAdultmedicine.medical_specialtyEfficacyAnti-HIV AgentsRITONAVIREmtricitabineTENOFOVIR ALAFENAMIDELAMIVUDINETenofovir alafenamideSingle-tablet regimen03 medical and health sciencesInternal medicineVirologymedicineVIH (Virus)HumansSwitch studyProtease InhibitorsTenofovirDarunavirAgedPharmacologyScience & Technology030306 microbiologybusiness.industryHIV (Viruses)AdenineDarunavir/cobicistat/emtricitabine/TAFAntiretroviral agentsCOBICISTATMAINTENANCEchemistry[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieHIV-1RitonavirCobicistat[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessRESISTANCE
researchProduct

The anomalous magnetic moment of positive and negative muons

1977

Abstract The anomalous g -factor a ≡ ( g −2)/2 has been measured for muons of both charges in the Muon Storage Ring at CERN. The two results, a μ + = 1165910(12) × 10 −9 and a μ − = 1165936(12) × 10 −9 , are in good agreement with each other, and combine to give a mean a μ = 1165922(9) × 10 −9 , which is very close to the most recent theoretical prediction 1165921(10) × 10 −9 . For the experimental results, the total statistical and systematic error is given. The measurements thus confirm the remarkable QED calculation plus hadronic contribution, and serve as a precise verification of the CPT theorem for muons.

PhysicsParticle physicsNuclear and High Energy PhysicsMuonLarge Hadron ColliderMagnetic momentAnomalous magnetic dipole momentCPT symmetryg factorHadronNuclear physicsHigh Energy Physics::ExperimentParticle Physics - ExperimentStorage ringPhysics Letters B
researchProduct

The πd scattering length from Kα X-rays

1974

Abstract X-rays from the K α transition (2P → 1S) of the π − d mesic atom have been observed. Their energy, 2592.8 −2.0 +1.6 , has been measured by the critical absorber technique, using the M V absorption edge in bismuth. The strong interaction shift in the 1S state is −4.8 eV, corresponding to a scattering length a ( π d) = −(0.052 −0.017 +0.022 ) m π −1 , in agreement with recent calculations. The intensity ratio K α /K total = 0.548 ± 0.015.

Nuclear reactionPhysicsNuclear and High Energy PhysicsAbsorption edgechemistryAtomStrong interactionchemistry.chemical_elementScattering lengthAtomic physicsIntensity ratioSpectral lineBismuthPhysics Letters B
researchProduct

Final report on the CERN muon storage ring including the anomalous magnetic moment and the electric dipole moment of the muon, and a direct test of r…

1978

Abstract A comprehensive description of the muon storage ring and its operation is given, and the final results of the experiment are presented and discussed. The anomalous magnetic moments of positive and negative muons are found to be aμ+ = 1165911(11) × 10−9 and aμ− = 1165937(12) × 10−9 giving an average value for muons of aμ = 1165924(8.5) × 10−9. The electric dipole moments were also measured with the results Dμ+= (8.6 ± 4.5) × 10−9e · cm and Dμ− = (0.8 ± 4.3) × 10−19e · cm. Under the assumption of the CPT theorem these yield a weighted average of Dμ = (3.7 ± 3.4) × 10−19e · cm. Finally the time transformation of special relativity is shown to be valid to (0.8 ± 0.7) × 10−3 at γ ≅ 29.3…

Nuclear physicsPhysicsNuclear and High Energy PhysicsDipoleElectric dipole momentParticle physicsMuonMagnetic momentAnomalous magnetic dipole momentCPT symmetryTime dilationParticle Physics - ExperimentStorage ringNuclear Physics B
researchProduct

Measurements of relativistic time dilatation for positive and negative muons in a circular orbit

1977

The lifetimes of both positive and negative relativistic (γ = 29.33) muons have been measured in the CERN Muon Storage Ring with the results τ+ = 64.419 (58) µs, τ− = 64.368 (29) µs The value for positive muons is in accordance with special relativity and the measured lifetime at rest: the Einstein time dilation factor agrees with experiment with a fractional error of 2×10−3 at 95% confidence. Assuming special relativity, the mean proper lifetime for μ− is found to be τ0− = 2.1948(10) µs the most accurate value reported to date. The agreement of this value with previously measured values of τ0+ confirms CPT invariance for the weak interaction in muon decay.

Nuclear physicsPhysicsParticle physicsMultidisciplinaryMuonCPT symmetryTime dilation of moving particlesHigh Energy Physics::ExperimentTime dilationCircular orbitSpecial relativityWeak interactionStorage ringNature
researchProduct